Key Takeaways
- Boards need visibility into assumptions and risk, not every launch tactic.
- A board-ready strategy connects market reality to organization, investment and milestones.
- Name residual risks and what would change management’s recommendation.
- Independent commercial perspective can strengthen board confidence before commitments lock in.
Biotechnology boards do not need to manage commercialization day to day. They do need enough clarity to approve investment, challenge assumptions and understand residual risk.
A board-ready commercial strategy is therefore an executive decision document—not a promotional plan. PharmaKonsult supports this through board and investor commercial advisory.
What the Board Package Should Include
- real addressable patient logic
- adoption and access pathway
- competitive outlook at launch
- organization and leadership plan
- investment range and sequencing
- milestones and governance
- five greatest commercial risks
- strategic alternatives if assumptions change
Use the commercial readiness checklist and board readiness questions as preparation tools.
Common Board Presentation Mistakes
Over-indexing on epidemiology, under-explaining access, presenting organization as a hiring wishlist and leaving risks unnamed are recurring problems. Boards should leave with decision clarity—not only optimism.
About Joseph McCoy
Joseph McCoy is Founder and Principal Consultant of PharmaKonsult and an executive commercial strategy advisor with more than three decades of pharmaceutical and biotechnology commercial leadership experience across neuroscience, rare disease, endocrinology, institutional healthcare and specialty pharmaceuticals.
